Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Spotify Technology (SPOT) Price & Performance

Charles River Laboratories Intl. IncTrade
Spotify TechnologyTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Spotify Technology — how do they compare? Charles River Laboratories Intl. Inc trades at $284.91 (market cap $13.46B), while Spotify Technology trades at $490.8 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 7.7× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.

CRLSPOT
Market Cap
$13.46B$103.00B
Sector
HealthMedia
52-Week High
$282.00$738.53
52-Week Low
$145.57$412.75
Enterprise Value
$16.30B$92.70B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.

The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.

Spotify Technology

Spotify (SPOT) trades at $511.82, up 4.85% with a bullish technical outlook. The company reported strong Q2 2026 results with revenue growth and record gross margins, though earnings missed estimates due to higher AI and marketing costs. Analyst consensus is bullish with a $598.20 price target, supported by 61.5% buy ratings. Recent news highlights Spotify's initiative to label AI-generated artists, enhancing platform transparency.

The outlook remains positive with robust subscriber growth and monetization efforts, but risks include competitive pressures and cost management. Upside potential exists if execution continues, while misses on user growth or margin targets could weigh on the stock. The current valuation reflects optimism for sustained profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Spotify Technology

Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.

Read more on SPOT